pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
DUPIXENT · news · pharmadog
← back to DUPIXENT
News mentioning DUPIXENT
44
stories
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 30, 26
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
endpoints
Jul 30, 26
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
Jul 30, 26
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
Jul 30, 26
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
Jul 30, 26
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
Jul 24, 26
Sanofi halts development of troubled immune drug in eczema
biopharma dive
Jul 24, 26
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
Jul 24, 26
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
endpoints
Jul 24, 26
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jun 10, 26
Sanofi stops immune drug trial in latest research setback
biopharma dive
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
Apr 23, 26
Sanofi posts upbeat sales as R&D pressure builds
biopharma dive
← prev
page 2 of 2
next →
